Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.

Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA.

Ann Intern Med. 2006 May 2;144(9):660-4. Retraction in: Ann Intern Med. 2015 Dec 1;163(11):884.

PMID:
16670135
3.

Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.

Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, Reid CM, Golledge J, Kingwell BA.

JAMA. 2013 Feb 6;309(5):453-60. doi: 10.1001/jama.2012.216237. Retraction in: JAMA. 2015 Oct 13;314(14):1520-1.

4.

Summaries for patients. Ramipril improves walking ability in patients with peripheral arterial disease.

[No authors listed]

Ann Intern Med. 2006 May 2;144(9):I24. No abstract available. Retraction in: Ann Intern Med. 2015 Dec 1;163(11):884.

PMID:
16670129
5.

Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients.

Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA.

J Hypertens. 2008 May;26(5):1037-42. doi: 10.1097/HJH.0b013e3282f8e3b6. Retraction in: J Hypertens. 2015 Dec;33(12):2552.

PMID:
18398348
6.

Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.

Shahin Y, Cockcroft JR, Chetter IC.

Br J Surg. 2013 Aug;100(9):1154-63. doi: 10.1002/bjs.9198.

PMID:
23842829
7.

Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.

Ahimastos AA, Latouche C, Natoli AK, Reddy-luthmoodoo M, Golledge J, Kingwell BA.

Circ Res. 2014 Mar 28;114(7):1144-55. doi: 10.1161/CIRCRESAHA.114.302420. Epub 2014 Jan 7. Retraction in: Circ Res. 2015 Sep 11;117(7):e64.

9.

Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.

Poole J, Mavromatis K, Binongo JN, Khan A, Li Q, Khayata M, Rocco E, Topel M, Zhang X, Brown C, Corriere MA, Murrow J, Sher S, Clement S, Ashraf K, Rashed A, Kabbany T, Neuman R, Morris A, Ali A, Hayek S, Oshinski J, Yoon YS, Waller EK, Quyyumi AA.

JAMA. 2013 Dec 25;310(24):2631-9. doi: 10.1001/jama.2013.282540.

PMID:
24247554
10.

Effect of ramipril on renal function in patients with intermittent claudication.

Hobbs SD, Claridge MW, Wilmink AB, Adam DJ, Thomas ME, Bradbury AW.

Vasc Health Risk Manag. 2008;4(2):471-5.

11.

The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.

O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV.

J Vasc Surg. 2009 May;49(5):1226-34. doi: 10.1016/j.jvs.2008.11.098. Epub 2009 Feb 14.

12.

Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial.

Gardner CD, Taylor-Piliae RE, Kiazand A, Nicholus J, Rigby AJ, Farquhar JW.

J Cardiopulm Rehabil Prev. 2008 Jul-Aug;28(4):258-65. doi: 10.1097/01.HCR.0000327184.51992.b8.

13.

Peripheral arterial disease symptom subtype and walking impairment.

Collins TC, Petersen NJ, Suarez-Almazor M.

Vasc Med. 2005 Aug;10(3):177-83.

PMID:
16235770
14.

The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.

Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR.

J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. Epub 2006 Nov 28.

15.

PoleStriding exercise and vitamin E for management of peripheral vascular disease.

Collins EG, Edwin Langbein W, Orebaugh C, Bammert C, Hanson K, Reda D, Edwards LC, Littooy FN.

Med Sci Sports Exerc. 2003 Mar;35(3):384-93.

PMID:
12618567
16.

Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture.

Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA.

Hypertension. 2005 Jun;45(6):1194-9. Epub 2005 May 16. Retraction in: Hypertension. 2016 Jan;67(1):e1.

17.

Effects of a long-term exercise program on lower limb mobility, physiological responses, walking performance, and physical activity levels in patients with peripheral arterial disease.

Crowther RG, Spinks WL, Leicht AS, Sangla K, Quigley F, Golledge J.

J Vasc Surg. 2008 Feb;47(2):303-9. doi: 10.1016/j.jvs.2007.10.038.

18.

Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease.

Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S; HOPE study investigators.

Eur Heart J. 2004 Jan;25(1):17-24.

PMID:
14683738
19.

A pilot exercise intervention to improve lower extremity functioning in peripheral arterial disease unaccompanied by intermittent claudication.

McDermott MM, Tiukinhoy S, Greenland P, Liu K, Pearce WH, Guralnik JM, Unterreiner S, Gluckman TJ, Criqui MH, Ferrucci L.

J Cardiopulm Rehabil. 2004 May-Jun;24(3):187-96.

PMID:
15235301
20.

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.

Mohler ER 3rd, Hiatt WR, Creager MA.

Circulation. 2003 Sep 23;108(12):1481-6. Epub 2003 Sep 2.

Supplemental Content

Support Center